Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus H CORT.
DEXAMETHASONE SODIUM PHOSPHATE vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a glucocorticoid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
4-20 mg IV or IM every 4-6 hours; for cerebral edema: 10 mg IV followed by 4 mg IM/IV every 6 hours; for shock: 20 mg IV initially then 2-6 mg/kg IV bolus or 40 mg IV every 2-6 hours as needed.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; however, the duration of action extends beyond the plasma half-life due to intracellular receptor-mediated effects.
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 30-40%.
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category D/X
Category C
Corticosteroid
Corticosteroid